BioticsAI founder shares FDA approval and healthcare startup challenges
Original: FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder
Why This Matters
Demonstrates successful navigation of FDA approval process for AI medical devices
BioticsAI CEO Robhy Bustami discussed building AI ultrasound technology for fetal abnormality detection. The company gained FDA approval in January 2026 after winning TechCrunch Startup Battlefield in 2023 with a prototype built for under $100,000.
BioticsAI develops an AI copilot for ultrasound that helps detect fetal abnormalities in a field with high misdiagnosis rates. CEO Robhy Bustami explained how the company navigated healthcare regulations by integrating FDA approval considerations from day one rather than building first and addressing regulation later. The team worked closely with clinicians, collected large-scale datasets, and ran structured clinical studies before submission. They engaged early with regulators through pre-submission meetings to align on study design and expectations. The biggest internal challenge was keeping teams motivated during long timelines before major milestones. Bustami emphasized building alignment across engineers, clinicians, and researchers while ensuring everyone could see incremental wins from clinical studies to healthcare partnerships.